Click Therapeutics and Indivior will develop a digital solution for treating substance use disorders, starting with opioid use disorders. Click already signed partnership deals with Otsuka and Verily and Boehringer Mannheim to co-develop digital therapeutics for patients with schizophrenia and major depressive disorder.

Restructuring Edition: Impel eliminated R&D spending earlier this year to focus on Trudhesa commercialization, but is examining all options, including bankruptcy, as its funding runs out. Also, Alaunos, BioXcel and others announce job cuts and strategic shifts during second quarter updates.

Exciting early results in gene editing contrast with issues around traditional gene therapies, including non-responders, safety and questions over the duration of efficacy.

What is the difference between companies with franchises that rise and then fall into obscurity, and those that keep on rising even after loss of exclusivity?